Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.009
Buy
RSI(14)
61.088
Neutral
STOCH(KDJ)(9,3,3)
57.700
Sell
ATR(14)
0.136
Low Volatility
CCI(14)
9.844
Neutral
Williams %R
49.991
Neutral
TRIX(12,20)
0.877
Sell
StochRSI(14)
0.000
Oversold
Oramed Pharmaceuticals Inc
ORMP2.985USD
+0.055+1.88%
Market hours （ET）Quotes delayed by 15 min
121.90MMarket Cap
2.84P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Oramed Pharmaceuticals Inc
Currency: USD Updated: 2025-12-19Key Insights
Oramed Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 167/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 3.25.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Oramed Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
3.250
Target Price
+36.55%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Oramed Pharmaceuticals Inc Highlights
StrengthsRisks
Oramed Pharmaceuticals Inc. is a pharmaceutical company engaged in the research and development of pharmaceutical solutions with a technology platform. The Company has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. It is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is 2.79, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 7.28M shares, decreasing 14.63% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 148.90K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of Oramed Pharmaceuticals Inc is 9.07, ranking 22/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.57
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.76
Oramed Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of Oramed Pharmaceuticals Inc is 7.75, ranking 88/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is 2.79, which is 836.27% below the recent high of 26.12 and 600.82% above the recent low of -13.97.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 167/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19No earnings forecast score is currently available for Oramed Pharmaceuticals Inc. The Biotechnology & Medical Research industry's average is 8.02. The average price target for Oramed Pharmaceuticals Inc is 3.25, with a high of 3.25 and a low of 3.25.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
No Data
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of Oramed Pharmaceuticals Inc is 9.06, ranking 48/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.29 and the support level at 2.49, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.020
Sell
MA10
2.948
Buy
MA20
2.843
Buy
MA50
2.546
Buy
MA100
2.407
Buy
MA200
2.316
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of Oramed Pharmaceuticals Inc is 3.00, ranking 197/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 18.26%, representing a quarter-over-quarter decrease of 46.51%. The largest institutional shareholder is James Simons, holding a total of 148.90K shares, representing 0.37% of shares outstanding, with 7.25% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of Oramed Pharmaceuticals Inc is 3.68, ranking 137/404 in the Biotechnology & Medical Research industry. The company's beta value is 1.17. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.18
VaR
+6.33%
240-Day Maximum Drawdown
+23.08%
240-Day Volatility
+59.86%
Return
Best Daily Return
60 days
+12.03%
120 days
+12.03%
5 years
+44.37%
Worst Daily Return
60 days
-3.81%
120 days
-6.67%
5 years
-76.46%
Sharpe Ratio
60 days
+1.81
120 days
+1.38
5 years
+0.22
Risk Assessment
Maximum Drawdown
240 days
+23.08%
3 years
+61.74%
5 years
+94.25%
Return-to-Drawdown Ratio
240 days
+0.85
3 years
+0.23
5 years
-0.15
Skewness
240 days
+1.86
3 years
+1.00
5 years
-1.93
Volatility
Realised Volatility
240 days
+59.86%
5 years
+104.78%
Standardised True Range
240 days
+3.80%
5 years
+15.88%
Downside Risk-Adjusted Return
120 days
+319.10%
240 days
+319.10%
Maximum Daily Upside Volatility
60 days
+52.01%
Maximum Daily Downside Volatility
60 days
+26.53%
Liquidity
Average Turnover Rate
60 days
+0.18%
120 days
+0.18%
5 years
--
Turnover Deviation
20 days
-51.31%
60 days
-51.50%
120 days
-51.00%
Peer Comparison
Biotechnology & Medical Research
Oramed Pharmaceuticals Inc
ORMP
5.91 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Oramed Pharmaceuticals Inc?
The TradingKey Stock Score provides a comprehensive assessment of Oramed Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Oramed Pharmaceuticals Inc’s performance and outlook.
How do we generate the financial health score of Oramed Pharmaceuticals Inc?
To generate the financial health score of Oramed Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Oramed Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Oramed Pharmaceuticals Inc.
How do we generate the company valuation score of Oramed Pharmaceuticals Inc?
To generate the company valuation score of Oramed Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Oramed Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Oramed Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Oramed Pharmaceuticals Inc.
How do we generate the earnings forecast score of Oramed Pharmaceuticals Inc?
To calculate the earnings forecast score of Oramed Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Oramed Pharmaceuticals Inc’s future.
How do we generate the price momentum score of Oramed Pharmaceuticals Inc?
When generating the price momentum score for Oramed Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Oramed Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for Oramed Pharmaceuticals Inc.
How do we generate the institutional confidence score of Oramed Pharmaceuticals Inc?
To generate the institutional confidence score of Oramed Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Oramed Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Oramed Pharmaceuticals Inc.
How do we generate the risk management score of Oramed Pharmaceuticals Inc?
To assess the risk management score of Oramed Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Oramed Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Oramed Pharmaceuticals Inc.
